Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | February 2009 |
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
The purpose of this study is to establish the safety and optimal dose of orally administered
PCI-32765 in patients with recurrent B cell lymphoma.
We found this trial at
11
sites
1 South Prospect Street
Burlington, Vermont 05401
Burlington, Vermont 05401
802-656-8990
Click here to add this to my saved trials
University of Chicago One of the world's premier academic and research institutions, the University of...
Click here to add this to my saved trials
5303 Harry Hines Boulevard
Dallas, Texas 75390
Dallas, Texas 75390
(214) 648-3111
UT Soutwestern Medical Center at Dallas UT Southwestern Medical Center is distinctive for its overall...
Click here to add this to my saved trials
National Cancer Institute (NCI) The National Cancer Institute (NCI) is part of the National Institutes...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Stanford university Hospital and Clinics Throughout our history, we have pioneered medical advances that save...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials